Kailera Therapeutics
KLRA
10.53
-0.30
-2.77%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
10.53
-0.30
-2.77%
Live - 5344 symbols - heartbeat 366s ago
· 2026-10-07 19:54
After-hours
10.53
0.00%
- Market cap
- 1.37B
- P/E (TTM)i
- -4.67
- P/Bi
- 1.22
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on KLRA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 99.29% -0.06pp
- Institutions
- 120
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund45.26%
Mutual Fund20.59%
Hedge Fund16.41%
Public Company9.38%
Government Pension Fund5.66%
Private Company1.97%
Other0.68%
Top holders as of 2026-06-30
Bain Capital, LP
20.25% · 26.26M sh
Bain Capital Life Sciences Investors, LLC
17.42% · 22.58M sh
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
8.88% · 11.51M sh
RTW Investments, LP
8.31% · 10.78M sh
Canada Pension Plan Investment Board
5.63% · 7.30M sh
Atlas Venture Advisors, Inc.
3.99% · 5.17M sh
FMR
3.06% · 3.97M sh
BlackRock
3.03% · 3.93M sh
T. Rowe Price Group, Inc.
2.73% · 3.53M sh
Citadel Advisors LLC
2.50% · 3.24M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
45 filings tracked · 23 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Bain Capital, LP | -- | 20.25% |
| Bain Capital Life Sciences Investors, LLC | -- | 17.42% |
| Ronald Renaud | Chief Executive Officer | 0.03% |
| John Milligan | Independent Non-Employee Chairman | -- |
| Canada Pension Plan Investment Board | -- | -- |
| Christopher Hite | Independent Director | -- |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | -- |
| Adam Koppel | Independent Director | -- |
| Martin MacKay | Independent Director | -- |
| Bain Capital Investors, LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-06 | Nur Nicholson | -- | Other Derivative Acquisition | +220,000 | $16.23 |
| 2026-07-05 | Kathleen Tregoning | Chief Corporate Affairs Officer | Other Derivative Acquisition | +175,000 | $23.30 |
| 2026-06-08 | Ronald Renaud | Chief Executive Officer | Derivative Exercise and Retained | +38,094 | $5.25 |
| 2026-04-19 | Bain Capital, LP | -- | Private Acquisition | +8,398,438 | $16.00 |
| 2026-04-19 | Bain Capital, LP | -- | Derivative Exercise and Retained | +17,857,143 | -- |
| 2026-04-19 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Derivative Exercise and Retained | +11,511,852 | -- |
| 2026-04-19 | RTW Investments, LP | -- | Private Acquisition | +500,000 | $16.00 |
| 2026-04-19 | RTW Investments, LP | -- | Derivative Exercise and Retained | +10,276,820 | -- |
| 2026-04-19 | Bain Capital Life Sciences Investors, LLC | -- | Private Acquisition | +1,562,500 | $16.00 |
| 2026-04-19 | Bain Capital Life Sciences Investors, LLC | -- | Derivative Exercise and Retained | +21,020,768 | -- |
| 2026-04-15 | John Milligan | Independent Non-Employee Chairman | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | John Milligan | Independent Non-Employee Chairman | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Canada Pension Plan Investment Board | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Christopher Hite | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | Christopher Hite | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Ronald Renaud | Chief Executive Officer | Other Derivative Acquisition | +600,000 | $16.00 |
| 2026-04-15 | Ronald Renaud | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Adam Koppel | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | Martin MacKay | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.